Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 20, 2025 | clinicaltrials |
| NCT01711632 | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT04601831 |
| 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL |
| completed |
| Phase 1 / Phase 2 |
| 14 |
| University of Texas Southwestern Medical CenterOTHER |
| 1 |
| Oct 16, 2025 |
| clinicaltrials |
| NCT02412228 | Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | completed | Phase 2 | 12 | John L. ReaganOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT01908777 | A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 47 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT05564052 | A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma(VEGA) | completed | Phase 2 | 36 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 7, 2025 | clinicaltrials |
| NCT03480438 | Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab(EWALL-BOLD) | completed | Phase 2 | 52 | Goethe UniversityOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02356159 | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 / Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03731832 | Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 66 | GWT-TUD GmbHOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT04318080 | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma(TIRHOL) | completed | Phase 2 | 46 | BeiGeneINDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT02858999 | Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70(LPP) | completed | Phase 2 | 40 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT02315768 | Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | completed | Phase 1 / Phase 2 | 32 | University of California, San DiegoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05267054 | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab | completed | Phase 1 / Phase 2 | 53 | BeiGeneINDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02500407 | A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 / Phase 2 | 713 | Genentech, Inc.INDUSTRY | 7 | Sep 12, 2025 | clinicaltrials |
| NCT03499808 | S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis | completed | Phase 2 | 43 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet(SELECT) | completed | Phase 2 | 54 | AmgenINDUSTRY | 8 | Sep 4, 2025 | clinicaltrials |
| NCT00498043 | A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma(LNH2007-3B) | completed | Phase 2 | 222 | Hospices Civils de LyonOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03525678 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | completed | Phase 2 | 221 | GlaxoSmithKlineINDUSTRY | 8 | Sep 3, 2025 | clinicaltrials |
| NCT03207555 | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00911183 | Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial(FRAIL-06) | completed | Phase 2 | 67 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03695471 | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT00357565 | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia | completed | Phase 2 | 34 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT02998476 | A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) | completed | Phase 2 | 60 | Incyte CorporationINDUSTRY | 11 | Aug 22, 2025 | clinicaltrials |
| NCT06149247 | HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | completed | Phase 2 | 10 | SoligenixINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01660607 | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | completed | Phase 1 / Phase 2 | 68 | Stanford UniversityOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) | completed | Phase 1 / Phase 2 | 307 | Incyte CorporationINDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT02916771 | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03834688 | Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age(PrE0405) | completed | Phase 2 | 33 | PrECOG, LLC.OTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02793544 | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | completed | Phase 2 | 80 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03739619 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 3 | Emory UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03331341 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT07102706 | Phase I Trial of GR1803 Injection in Patients With RRMM | completed | Phase 1 / Phase 2 | 76 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02278796 | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)(BEB) | completed | Phase 2 | 108 | Insel Gruppe AG, University Hospital BernOTHER | 2 | Aug 1, 2025 | clinicaltrials |
| NCT03496779 | Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | completed | Phase 2 | 71 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 30, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | University of MiamiOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04669210 | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT(PTCyRuxo) | completed | Phase 2 | 128 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | completed | Phase 2 | 48 | Dizal PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03133221 | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | completed | Phase 2 | 17 | University of Maryland, BaltimoreOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT02765854 | Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | completed | Phase 2 | 70 | Emory UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT01995669 | Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 66 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 20, 2025source: clinicaltrials